WT1 for the Detection of Minimal Residual Disease

Plain-language summary

This study examines the use of WT1 testing to detect the small number of remaining disease cells (minimal residual disease) after treatment in childhood leukemias. It enrolled patients under 21 with acute lymphoblastic leukemia, acute non-lymphoblastic leukemia, or chronic myelogenous leukemia. The research was conducted in Phase 2/Phase 3 and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

PHASE2/PHASE3

Status

Completed

Sponsor

Ann & Robert H Lurie Children's Hospital of Chicago

Intervention

WT 1 Testing

Start date

2/1/1999

Estimated completion

4/1/2006

Countries

United States

Related genes

Locations

• Chicago, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Age less than 21 years of age.
* Patients with the following diseases: Acute lymphoblastic Leukemia (ALL) at the time of diagnoses or relapse, Acute non-lymphoblastic leukemia (ANLL) at diagnosis or after relapse and Chronic Myelogenous leukemia in chronic or accelerated phase.
* Patients will be eligible for any of the available treatment protocols or protocols for stem cell transplantation, regardless of the source of stem cells.
* Patients or legal guardians will sign an Institutional Review Board (IRB) approved informed consent.
* Patients will have venous access or peripheral vein for sampling.